Cadila Healthcare Ltd

BSE - 532321
NSE - CADILAHC
ISIN - INE010B01027

Companies
Cadila Pharmaceuticals launches advanced Quadrivalent Influenza Vaccine
Companies
Jawed Zia named CEO of Cadila Pharmaceuticals’ domestic prescription business
Companies
Cadila Healthcare standalone Q2 net profit at ₹14 crore
Consolidated EBITDA at ₹861 crore, up 6 per cent y-o-y
Stocks
Stocks that will see action
Focus on SBI Cards, HCL Tech, ACE, Cadila Healthcare, Adani Ports, RPP Infra, Indian Sucrose
Stocks
Booster dose: Cadila share doubles in 18 months
Since vaccine development to EUA , Zydus Cadila stock surges 111%
Companies
Cadila Healthcare up 5% after DCGI approves Zydus Cadila’s ZyCoV-D Covid vaccine
With this approval, India now has its first Covid-19 vaccine for adolescents in the 12-18 age group
Stocks
LIC hikes stake marginally in Cadila Health, Alembic Pharma
FPIs, mutual funds cut stake during Q1
National
Zydus applies for emergency use nod for Covid-19 vaccine
Interim results from Phase III clinical trials demonstrate safety and efficacy for the 12-18 age group.
Companies
Zydus Cadila gets tentative USFDA nod to market lung cancer drug
The drug to be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Companies
Cadila Healthcare seeks regulatory approval for Covid-19 drug
A single dose repurposed drug, when taken early, could help Covid patients recover faster and avoid complications seen in the advanced stages of the disease.
Companies
Cadila standalone Q3 net falls 35% to ₹140 crore
News
Zydus Cadila’s ZyCov-D vaccine found to be ‘safe and immunogenic’
Company wraps up Phase-I/II trials, eyes start of Phase-III

Sign into Unlock benefits!

Access 10 free stories per month
Access to comment on every story
Sign up/Manage to our newsletters
Get notified by email for early preview to new features, discounts & offers